Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.40 |
| ▸ | CNR1 | P21554 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 3/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.39 |
| ▸ | REN | P00797 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | ICMT | O60725 | 1/20 | 0.37 |
| ▸ | IL1B | P01584 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.36 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3562254 | 0.83 | GAA (0.49) | CNR2CNR1GAA | |
| SCHEMBL3561211 | 0.79 | MEN1 (0.41) | CNR2CNR1CYSLTR2CYSLTR1 | |
| SCHEMBL3561208 | 0.79 | MEN1 (0.41) | CNR2CNR1CYSLTR2CYSLTR1 | |
| SCHEMBL13131417 | 0.74 | REN (0.45) | CNR2CNR1HTR2AHTR2CHTR2B | |
| SCHEMBL27774971 | 0.73 | CNR1 (0.41) | CNR2CNR1MCL1RENICMT | |
| SCHEMBL16264965 | 0.73 | CDC25A (0.57) | CNR2CNR1ICMTGAA | |
| SCHEMBL318745 | 0.72 | CNR1 (0.53) | CNR2CNR1MCL1ICMTGAA | |
| SCHEMBL15322768 | 0.71 | HTR2C (0.59) | HTR2AHTR2CHTR2B | |
| SCHEMBL10248359 | 0.71 | CNR1 (0.51) | CNR2CNR1MCL1RENICMT | |
| SCHEMBL20120027 | 0.70 | CMA1 (0.47) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1852420-B1 | Indole compounds for treating respiratory disorders | ONO PHARMACEUTICAL CO (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-7728023-B2 | Indole compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080188532-A1 | Indole Compound and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-07 | — | — | US | disclosed |
| EP-1852420-A1 | INDOLE COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188532-A1 | Indole Compound and Use Thereof | CYSLTR1, LTC4S, IDO1 | CNR2 283/4885CNR1 317/4885HTR2A 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.